Skip To Main Content
Yingxian Liu on Muck Rack

Yingxian Liu

As seen in: Color Research & Application, Nature, MDPI, Academic Radiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingxian

Contact Yingxian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multilevel synergistic anticancer mechanisms of Punica granatum L. peel polyphenols targeting the pan-cancer proliferation target PCNA: a combined analysis based on network pharmacology, molecular dynamics simulation, and UPLC-Q-TOF-HRMS

|
By Shijia Lu, Mengjia Yan, Huaying Du, Han Zhang, Yutong Zhang, Jinle Wang, Xue Yang, Zhi Qiao, Yiran Zhao, Yixin Wang, Ruizi Zhang, Shuyan Li, Yingxian Liu, Chendi Hua, Jinglei Cai, Jiying Du
| Nature Verified
Abstract Punica granatum L. peel is rich in tannins and flavonoids. Modern pharmacological studies have indicated its multi-target anticancer potential; however, the molecular recognition mechanisms between its active components and key targets remain to be systematically clarified.
Open in Who Shared Issue with article?

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial

|
By Yuchen Zhang, Man Nie, Yi Cao, Zhiming Li, He Huang, Guowei Li, Xiuhua Sun, Yan Gao, Xiaojie Fang, Bing Bai, Jun Cai, Lirong Li, Yingxian Liu, Sihua Peng, Huiqiang Huang, Yi Xia, Qingqing Cai
| Nature Verified
Abstract A combination of Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib and rituximab has shown promising efficacy in mantle cell lymphoma (MCL). This phase II trial evaluated the second-generation BTK inhibitor zanubrutinib plus rituximab as induction, followed by shortened chemoimmunotherapy as frontline treatment for MCL (NCT04624958). Eligible patients had histologically confirmed stage II–IV disease requiring immediate therapy and no prior MCL-related systemic treatment.
Open in Who Shared Issue with article?

Artificial Intelligence in CT for Predicting Cervical Lymph Node Metastasis in Papillary Thyroid Cancer Patients: A Meta-analysis

|
By Sixun Zenga, Yingxian Liu, Xinyi Duan, Xin Zhao, Xiangjuan Sun, Fenghua Zhang, Sixun Zeng
| Academic Radiology Verified
Abbreviations LNM (lymph node metastasis) PTC (papillary thyroid cancer) DECT (dual-energy CT) TP (true positive) TN (true negative) FP (false positive) FN (false negative) ROC (receiver operating characteristic) CI (confidence intervals) SROC (summary receiver operating characteristic) AI (artificial intelligence) AUC (area under the curve) Key Words Artificial intelligence Computed tomography Papillary thyroid cancer Lymph node metastasis Meta-analysis Get full text access Log in, subscribe...
Open in Who Shared Issue with article?
See all 6 articles